PMID- 38066029
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20240116
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Dec 8
TI  - Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients 
      with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: 
      an emulated target trial using nationwide cohort data in South Korea.
PG  - 21756
LID - 10.1038/s41598-023-48678-1 [doi]
LID - 21756
AB  - Novel hypoglycemic agents, sodium-glucose cotransporter 2 inhibitors (SGLT2i), 
      have shown protective effects against anthracycline (AC)-induced cardiotoxicity 
      and exhibit partial anticancer effects in animal models. However, clinical 
      evidence for this is scarce. This study aimed to evaluate whether SGLT2i improve 
      the clinical outcomes of patients with type 2 diabetes mellitus (T2DM) undergoing 
      AC-containing chemotherapy. A total of 81,572 patients who underwent AC 
      chemotherapy between 2014 and 2021 were recruited from a nationwide Korean 
      cohort. Patients were classified into three groups: patients with T2DM taking 
      SGLT2i (n = 780) and other hypoglycemic agents excluding SGLT2i (non-SGLT2i; 
      n = 3,455) during AC chemotherapy, and the non-DM group (n = 77,337). The 
      clinical outcome was a composite of heart failure hospitalization, acute 
      myocardial infarction, ischemic stroke, and death. After propensity score 
      matching, 779 SGLT2i users were compared with 7800 non-DM patients and 2,337 
      non-SGLT2i users. The SGLT2i group had better composite outcomes compared with 
      the non-DM group (adjusted hazard ratio [HR] = 0.35, 95% confidence interval [95% 
      CI] = 0.25-0.51) and compared with the non-SGLT2i group (adjusted HR = 0.47, 95% 
      CI = 0.32-0.69). In conclusion, SGLT2i may contribute to improving clinical 
      outcomes in patients with T2DM undergoing AC-containing chemotherapy, through an 
      emulated target trial using Korean nationwide cohort data.
CI  - (c) 2023. The Author(s).
FAU - Hwang, Hui-Jeong
AU  - Hwang HJ
AD  - Department of Cardiology, Kyung Hee University College of Medicine, Kyung Hee 
      University Hospital at Gangdong, Seoul, 05278, Republic of Korea. 
      neonic7749@khu.ac.kr.
FAU - Kim, Minji
AU  - Kim M
AD  - Center for Digital Health, Medical Science Research Institute, Kyung Hee 
      University Medical Center, Kyung Hee University College of Medicine, Seoul, 
      02447, Republic of Korea.
AD  - Department of Regulatory Science, Kyung Hee University, Seoul, Republic of Korea.
FAU - Jun, Ji Eun
AU  - Jun JE
AD  - Department of Endocrinology and Metabolism, Kyung Hee University Hospital at 
      Gangdong, Kyung Hee University School of Medicine, Seoul, Republic of Korea.
FAU - Yon, Dong Keon
AU  - Yon DK
AD  - Center for Digital Health, Medical Science Research Institute, Kyung Hee 
      University Medical Center, Kyung Hee University College of Medicine, Seoul, 
      02447, Republic of Korea. yonkkang@gmail.com.
AD  - Department of Regulatory Science, Kyung Hee University, Seoul, Republic of Korea. 
      yonkkang@gmail.com.
LA  - eng
GR  - HE23C002800/Ministry of Health and Welfare/
GR  - 21153MFDS601/Ministry of Food and Drug Safety/
PT  - Journal Article
DEP - 20231208
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Anthracyclines)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Polyketides)
RN  - IY9XDZ35W2 (Glucose)
RN  - 9NEZ333N27 (Sodium)
SB  - IM
MH  - Animals
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Anthracyclines
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Hypoglycemic Agents/therapeutic use
MH  - Republic of Korea/epidemiology
MH  - Antibiotics, Antineoplastic
MH  - *Polyketides
MH  - Glucose
MH  - Sodium
MH  - Retrospective Studies
PMC - PMC10709414
COIS- The authors declare no competing interests.
EDAT- 2023/12/09 05:43
MHDA- 2023/12/17 09:44
PMCR- 2023/12/08
CRDT- 2023/12/08 23:30
PHST- 2023/10/26 00:00 [received]
PHST- 2023/11/29 00:00 [accepted]
PHST- 2023/12/17 09:44 [medline]
PHST- 2023/12/09 05:43 [pubmed]
PHST- 2023/12/08 23:30 [entrez]
PHST- 2023/12/08 00:00 [pmc-release]
AID - 10.1038/s41598-023-48678-1 [pii]
AID - 48678 [pii]
AID - 10.1038/s41598-023-48678-1 [doi]
PST - epublish
SO  - Sci Rep. 2023 Dec 8;13(1):21756. doi: 10.1038/s41598-023-48678-1.